HBK Sorce Advisory’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $451K | Sell |
5,441
-351
| -6% | -$29.1K | 0.01% | 360 |
|
|
2025
Q1 | $470K | Buy |
5,792
+1,310
| +29% | +$106K | 0.01% | 351 |
|
|
2024
Q4 | $404K | Buy |
4,482
+279
| +7% | +$25.1K | 0.01% | 383 |
|
|
2024
Q3 | $415K | Sell |
4,203
-119
| -3% | -$11.8K | 0.01% | 381 |
|
|
2024
Q2 | $401K | Sell |
4,322
-216
| -5% | -$20K | 0.01% | 370 |
|
|
2024
Q1 | $431K | Buy |
4,538
+113
| +3% | +$10.7K | 0.02% | 367 |
|
|
2023
Q4 | $395K | Buy |
4,425
+267
| +6% | +$23.8K | 0.02% | 361 |
|
|
2023
Q3 | $304K | Buy |
4,158
+37
| +0.9% | +$2.7K | 0.01% | 416 |
|
|
2023
Q2 | $343K | Sell |
4,121
-25
| -0.6% | -$2.08K | 0.01% | 406 |
|
|
2023
Q1 | $316K | Sell |
4,146
-3,450
| -45% | -$263K | 0.01% | 421 |
|
|
2022
Q4 | $631K | Buy |
7,596
+3,759
| +98% | +$312K | 0.02% | 371 |
|
|
2022
Q3 | $304K | Buy |
3,837
+1,006
| +36% | +$79.7K | 0.02% | 361 |
|
|
2022
Q2 | $210K | Buy |
2,831
+308
| +12% | +$22.8K | 0.02% | 420 |
|
|
2022
Q1 | $227K | Buy |
2,523
+175
| +7% | +$15.7K | 0.01% | 478 |
|
|
2021
Q4 | $263K | Buy |
2,348
+3
| +0.1% | +$336 | 0.01% | 489 |
|
|
2021
Q3 | $295K | Sell |
2,345
-60
| -2% | -$7.55K | 0.02% | 442 |
|
|
2021
Q2 | $326K | Buy |
2,405
+10
| +0.4% | +$1.36K | 0.02% | 427 |
|
|
2021
Q1 | $325K | Buy |
2,395
+222
| +10% | +$30.1K | 0.02% | 383 |
|
|
2020
Q4 | $306K | Buy |
2,173
+100
| +5% | +$14.1K | 0.02% | 368 |
|
|
2020
Q3 | $231K | Buy |
+2,073
| New | +$231K | 0.02% | 390 |
|
|
2018
Q4 | – | Sell |
-2,331
| Closed | -$224K | – | 423 |
|
|
2018
Q3 | $224K | Buy |
2,331
+44
| +2% | +$4.23K | 0.03% | 356 |
|
|
2018
Q2 | $218K | Buy |
+2,287
| New | +$218K | 0.03% | 353 |
|